Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Galderma R&D
Age
17–35
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant with clinical diagnosis of acne vulgaris on the face as defined by (excluding the nose and middle zone of approximately 2 centimeter \[cm\]):
1. Investigator's Global Assessment (IGA) score of 3 (Moderate) or 4 (Severe), with the same score on both sides of the face; and
2. A minimum of 20 inflammatory lesions (papules and pustules) in total with at least 10 on each side; and
3. No more than 2 nodules (greater than or equal to \[\>=\] 1 cm in diameter) on the face; and
4. A minimum of 10 atrophic acne scars in total (\>2 mm)
Participant with a symmetrical number of the following lesions/scars on the whole face:
1. Inflammatory and non-inflammatory lesions; and
2. Atrophic acne scars (minimum of 4 scars per half-face)
The participant is a female of non-childbearing potential
If a female of childbearing, potential uses oral contraceptives that are also approve for treating acne vulgaris
You may not be if
Participant with acne conglobata, acne fulminans, secondary acne, nodulocystic acne and acne requiring systemic treatment
Participant with any acne cyst on the face or with more than 3 excoriated acne lesions
Participant with known active or chronic allergies or suspected allergy to trifarotene or excipients of the formulation
Participant with facial dermal conditions (for example, tattoo, skin abrasion, eczema, sunburned skin, scars, nevi, etc.) that may interfere with study assessments in the opinion of the investigator
Participant with known impaired hepatic or renal functions, based on medical history
Clareo Health | Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
